[HTML][HTML] Hepatocellular carcinoma: therapy and prevention

HE Blum - World journal of gastroenterology, 2005 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide.
The major etiologies and risk factors for the development of HCC are well defined and some …

[HTML][HTML] Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus

T Wen, C Jin, A Facciorusso, M Donadon… - … surgery and nutrition, 2018 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading
cause of cancer-related death in the world. However, 40–70% patients eventually suffer from …

Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition)

J Zhou, HC Sun, Z Wang, WM Cong, JH Wang… - Liver cancer, 2018 - karger.com
Abstract Background: Hepatocellular carcinoma (HCC)(about 85–90% of primary liver
cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis …

Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study

Z Wang, Z Ren, Y Chen, J Hu, G Yang, L Yu… - Clinical Cancer …, 2018 - AACR
Purpose: The survival of patients with hepatocellular carcinoma (HCC) recurrence after
curative resection is usually poor. We sought to evaluate the safety and efficacy of adjuvant …

[PDF][PDF] Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection

YF Sun, Y Xu, XR Yang, W Guo, X Zhang, SJ Qiu… - …, 2013 - Wiley Online Library
Epithelial cell adhesion molecule–positive (EpCAM+) hepatocellular carcinoma (HCC) cells
may constitute a tumor‐initiating subpopulation in tumorigenic cell lines and HCC …

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma

D Hui, L Qiang, W Jian, Z Ti, K Da-Lu - Digestive and liver disease, 2009 - Elsevier
BACKGROUND: With a resistance to conventional chemotherapy and radiotherapy,
hepatocellular carcinoma has a high recurrence rate after radical resection. Adjuvant …

[HTML][HTML] A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma

W Chen, T Ma, J Zhang, X Zhang, W Chen, Y Shen… - Hpb, 2020 - Elsevier
Background The aim of this study was to systematically evaluate and determine those
patients with hepatocellular carcinoma (HCC) that would benefit from the administration of …

CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery

XR Yang, Y Xu, B Yu, J Zhou, JC Li, SJ Qiu, YH Shi… - Clinical Cancer …, 2009 - AACR
Purpose: To investigate the role of CD24 in tumor invasion and prognostic significance in
hepatocellular carcinoma (HCC). Experimental Design: CD24 expression was measured in …

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular …

C Zhong, R Guo, J Li, M Shi, W Wei, M Chen… - Journal of cancer …, 2009 - Springer
Purpose Hepatectomy is considered as the potentially curative treatment for hepatocellular
carcinoma (HCC) and used in some selected Stage IIIA HCC, which include multiple tumors …

Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate …

X Yin, L Zhang, YH Wang, BH Zhang, YH Gan, NL Ge… - BMC cancer, 2014 - Springer
Background This study was designed to evaluate the effectiveness of radiofrequency
ablation in patients with intermediate (BCLC B) stage hepatocellular carcinoma who …